Diffuse large B-cell lymphoma trials in Colombia

3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Where

  Bogotá, Cali, Medellín, Montería, Pereira

  Age

  18 years and over

  People

  1,046 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06717347 · EU 2024-515566-13-00
• Phase 2/3Taking people
  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Where

  Bogotá, Cali, Medellín, Montería, Pereira

  Age

  18 years and over

  People

  290 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT05139017 · EU 2022-502646-27-00
• Phase 1/2Taking people
  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  Where

  Barranquilla, Medellín, Montería

  Age

  6 months to 25 years

  People

  90 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06395103 · EU 2023-507178-41-00